prikaz prve stranice dokumenta Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
  Download
PDF 1.02 MB
Professional paper - Professional paper
Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
Acta clinica Croatica, 57. (2018), 1.; 190-215. https://doi.org/10.20471/acc.2018.57.01.27
Jakšić, Branimir; Pejša, Vlatko; Ostojić-Kolonić, Slobodanka; Kardum-Skelin, Ika; Bašić-Kinda, Sandra; Coha, Božena; Gverić-Krečak, Velka; Vrhovac, Radovan; Jakšić, Ozren; Aurer, Igor; Sinčić-Petričević, Jasminka; Načinović-Duletić, Antica; Nemet, Damir

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Jakšić, B., Pejša, V., Ostojić Kolonić, S., Kardum Skelin, I., Bašić Kinda, S., Coha, B. ... Nemet, D. (2018). Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. Acta clinica Croatica, 57.. (1.), 190-215. doi: 10.20471/acc.2018.57.01.27

Jakšić, Branimir, et al. "Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017." Acta clinica Croatica, vol. 57., no. 1., 2018, pp. 190-215. https://doi.org/10.20471/acc.2018.57.01.27

Jakšić, Branimir, Vlatko Pejša, Slobodanka Ostojić Kolonić, Ika Kardum Skelin, Sandra Bašić Kinda, Božena Coha, Velka Gverić Krečak, et al. "Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017." Acta clinica Croatica 57., no. 1. (2018): 190-215. https://doi.org/10.20471/acc.2018.57.01.27

Jakšić, B., et al. (2018) 'Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017', Acta clinica Croatica, 57.(1.), pp. 190-215. doi: 10.20471/acc.2018.57.01.27

Jakšić B, Pejša V, Ostojić Kolonić S, Kardum Skelin I, Bašić Kinda S, Coha B, and sur.. Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. Acta clinica Croatica [Internet]. 2018 March 01 [cited 2024 May 10];57.(1.):190-215. doi: 10.20471/acc.2018.57.01.27

B. Jakšić, et al., "Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017", Acta clinica Croatica, vol. 57., no. 1., pp. 190-215, March 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:576386. [Accessed: 10 May 2024]

Metadata
Title (english)Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
Title (croatian)Smjernice za dijagnostiku i liječenje kronične limfocitne leukemije – Krohem B-CLL 2017.
AuthorBranimir Jakšić
AuthorVlatko Pejša
AuthorSlobodanka Ostojić-Kolonić
AuthorIka Kardum-Skelin
AuthorSandra Bašić-Kinda
AuthorBožena Coha
AuthorVelka Gverić-Krečak
AuthorRadovan Vrhovac
AuthorOzren Jakšić
AuthorIgor Aurer
AuthorJasminka Sinčić-Petričević
AuthorAntica Načinović-Duletić
AuthorDamir Nemet
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Recent developments in the diagnosis and treatment of chronic lymphocytic leukemia (B-CLL) have led to change of approach in clinical practice. New treatments have been approved based on the results of randomized multicenter trials for first line and for salvage therapy, and the results of numerous ongoing clinical trials are permanently providing new answers and further refining of therapeutic strategies. This is paralleled by substantial increase in understanding the disease genetics due to major advances in the next generation sequencing (NGS) technology. We define current position of the Croatian Cooperative Group for Hematologic Disease on diagnosis and treatment of CLL in the transition from chemo-immunotherapy paradigm into a new one that is based on new diagnostic stratification and unprecedented therapeutic results of B-cell receptor inhibitors (BRI) and Bcl-2 antagonists. This is a rapidly evolving field as a great number of ongoing clinical trials constantly accumulate and provide new knowledge. We believe that novel therapy research including genomic diagnosis is likely to offer new options that will eventually lead to time limited therapies without chemotherapy and more effective clinical care for B-CLL based on individualized precision medicine.
Abstract (croatian)
Nedavni događaji u dijagnostici i liječenju kronične limfocitne leukemije (B-KLL) doveli su do promjene pristupa u kliničkoj praksi. Nova liječenja su odobrena na temelju rezultata randomiziranih multicentričnih pokusa za prvu liniju terapije i za liječenje relapsa/refraktorne bolesti, a rezultati brojnih kliničkih pokusa u tijeku trajno doprinose daljnjem unaprjeđenju terapijskih strategija. Uz to prisutan je bitan porast razumijevanja genskih promjena bolesti zbog velikog napretka tehnologije nove generacije sekvencioniranja. Definiramo trenutni stav Hrvatske suradne skupine za hematološke bolesti o dijagnostici i liječenju B-KLL u sadašnjoj tranziciji iz kemo-imunoterapijske paradigme u novu koja se temelji na novoj dijagnostičkoj slojevitosti i izvrsnim terapijskim rezultatima inhibitora B-staničnih receptora (BRI) i Bcl-2 antagonista. To se područje brzo razvija kako velik broj kliničkih ispitivanja koja su u tijeku neprestance doprinosi i pruža nova znanja. Vjerujemo da će istraživanje novih terapija uz genomsku dijagnostiku pružiti nove mogućnosti koje će na kraju dovesti do vremenski ograničenog liječenja bez kemoterapije i do učinkovitije kliničke skrbi B-KLL na temelju individualizirane i precizne medicine.
Keywords (english)
Keywords (croatian)
Languageenglish
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleActa clinica Croatica
Numberingvol. 57., no. 1., pp. 190-215
p-ISSN0353-9466
e-ISSN1333-9451
DOIhttps://doi.org/10.20471/acc.2018.57.01.27
URN:NBNurn:nbn:hr:184:576386
Publication2018-03-01
Document URLhttps://hrcak.srce.hr/202242
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2018-06-27 12:17:12